Global Tyrosine Kinase Inhibitors Market 2024 Technology Scouting, Industry Insights, Business Outlook And Key Players Analysis Till 2033

The tyrosine kinase inhibitors market size has grown strongly in recent years. It will grow from $53.72 billion in 2023 to $58.69 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to discovery of tyrosine kinases, understanding cancer signaling pathways, approval of imatinib (gleevec), clinical success of early tkis, investment in research and development.

The tyrosine kinase inhibitors market size is expected to see strong growth in the next few years. It will grow to $81.41 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to growing healthcare investments, biomarker-driven therapies, drug delivery innovations, precision medicine paradigm, pediatric oncology focus. Major trends in the forecast period include resistance mitigation strategies, development of cns-penetrant tkis, non-oncology applications, liquid biopsies for monitoring, health economic considerations.

Market Overview -
Tyrosine kinase inhibitors (TKI) refer to a class of pharmaceuticals that block several ways protein kinases signal the transduction pathway's function. It is used in targeted therapy to target and kill cancer cell types while sparing healthy cells.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=11957&type=smp

The Rising Prevalence Of Cancer Boosts The Tyrosine Kinase Inhibitors Market
The increasing prevalence of cancer is expected to propel the growth of the tyrosine kinase inhibitors market going forward. Cancer refers to a broad collection of illnesses that begin in any organ or tissue of the body, where abnormal cells grow out of control, cross their usual boundaries to infect nearby body parts, and spread to other organs. The tyrosine kinase inhibitors are used in targeted therapy to target and kill cancer cell types by blocking tyrosine kinases that aid in preventing the growth of cancer cells. For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases increased from 1,898,160 in 2021 to 1,958,310 in 2023, reflecting a growth of 3.16%. Therefore, the increasing prevalence of cancer is driving the growth of the tyrosine kinase inhibitors market.

Competitive Landscape -
Major companies operating in the tyrosine kinase inhibitors market report are Pfizer Inc., Johnson And Johnson Private Limited., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd, Incyte Corporation, Dr. Reddy's Laboratories Ltd., Exelixis Inc., Array BioPharma Inc., Glenmark Pharmaceuticals Ltd, Blueprint Medicines Corporation, Loxo Oncology Inc., Rigel Pharmaceuticals Inc., Deciphera Pharmaceuticals LLC, Epizyme Inc., Turning Point Therapeutics Inc., Kura Oncology Inc., ArQule Inc.

Innovative Products Drive Momentum In The Tyrosine Kinase Inhibitors Market
Product innovations are a key trend gaining popularity in the tyrosine kinase inhibitor market. Major companies operating in the tyrosine kinase inhibitor market are adopting new technologies to sustain their position in the market. For instance, in October 2021, Novartis AG, a Switzerland-based pharmaceutical corporation, received approval from the Food and Drug Administration for the drug asciminib (Scemblix, Novartis AG) for individuals with chronic myeloid leukemia (Ph+ CML) that has the Philadelphia chromosome in the chronic phase (CP). Additionally, this inhibitor binds to a pocket different from the ATP-binding region of the kinase 9 to precisely and potently block BCR-ABL1. It offers the prospect of dual inhibition of BCR-ABL1 in conjunction with ATP-binding TKIs and the potential to overcome resistance to earlier TKIs.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/tyrosine-kinase-inhibitors-global-market-report

Key Segments -
The tyrosine kinase inhibitors market covered in this report is segmented -
1) By Type: BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, Other Types
2) By Distribution Channel: Hospital Pharmacy, Independent Pharmacies, Online Pharmacies
3) By Application: Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer, Other Applications

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.